Ignite Creation Date:
2024-05-06 @ 4:04 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04862260
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-22
First Post:
2021-04-06
Brief Title:
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
Sponsor:
CHU de Quebec-Universite Laval
Organization:
CHU de Quebec-Universite Laval
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Metastatic Cancer |
| Pancreatic Ductal Adenocarcinoma |
| Pancreatic Cancer |
| Pancreas Cancer |
Keywords:
| Name | View |
|---|---|
| FOLFIRINOX | View |
| Statin | View |
| Atorvastatin | View |
| Lipitor | View |
| PCSK9 monoclonal antibody | View |
| PCSK9 inhibitor | View |
| PCSK9 | View |
| Evolocumab | View |
| Repatha | View |
| Alirocumab | View |
| Praluent | View |
| Lipid droplets and vacuoles | View |
| NPC1L1 transporter | View |
| HMG Co A reductase | View |
| LDL receptor | View |
| LRP1 receptor | View |
| SRB1 receptor | View |
| Lipids | View |
| Cancer | View |
| Cholesterol | View |
| Pancreas cancer | View |
| PancreasPancreatic Cancer Metastatics | View |